PDCD1 and colorectal carcinoma: Recent clinical studies have shown that metastatic MSI-H/dMMR CRC is more likely to benefit from PD-1 inhibitors, whereas microsatellite stable (MSS)/mismatch repair proficient (pMMR) CRC shows minimal response (84).